-
Mashup Score: 0Early MMR With TKI Therapy Not Necessary to Normalize Survival in Patients Over 60 With CML | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination March 8, 2023 Khylia Marshall is a freelance journalist based in Tucson, Arizona. Achieving a major molecular response (MMR) within the first two years of initiating tyrosine kinase inhibitor (TKI) therapy…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1How I treat chronic-phase chronic myelogenous leukemia - 1 year(s) ago
Using a series of 5 illustrative cases, Berman updates current approaches to the treatment of chronic-phase chronic myeloid leukemia (CML) in the context of the
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
How I treat chronic-phase #ChronicMyelogenousLeukemia A beautiful review of this popular topic with case illustrations to describe how to treat👇 https://t.co/EGAyUSeSJ2 @MSKCancerCenter #TKI https://t.co/DLIfYTxcfd
-
-
Mashup Score: 12Hair Repigmentation Induced by Nilotinib | NEJM - 2 year(s) ago
Images in Clinical Medicine from The New England Journal of Medicine — Hair Repigmentation Induced by Nilotinib
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Even drug side effects can be welcome occasionally! When you’re #leukemia free and your hair color is back!!! Setting back the hair clock… now that’s a win for #TKI 🙌🏻 Hair Repigmentation Induced by #Nilotinib via @NEJM https://t.co/NQGTEvMtmJ https://t.co/YqYNRgbgrP
-
-
Mashup Score: 0
Researchers sought to determine if reducing the starting dose of TKI therapy in patients with metastatic RCC would improve tolerability without reducing efficacy.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A reduced starting dose of tyrosine kinase inhibitor therapy may provide similar efficacy, but with improved tolerability, compared with a full initial starting dose in patients with metastatic #renalCellCarcinoma. With @AUG_Health. https://t.co/iYJVcRaRQw #RCC #TKI
-
-
Mashup Score: 2Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma - A Single Institute Analysis - PubMed - 2 year(s) ago
The study findings highlight the effect of past anthracycline exposure and baseline BNP for pazopanib-associated HF. Although the study patients’ clinical outcomes were generally favorable, periodic monitoring of cardiac function using ultrasonic echocardiography or serum markers is essential to det …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
RT @kaufman_renato: https://t.co/4x8bpN2u55 @arjunkg @wcostacardio @RenatoVargas0 @Gabrielcata80 @franckthuny #cardioonc #TKI #HeartFailur…
-
-
Mashup Score: 11Duration of Deep Molecular Response Associated With Maintaining Treatment-Free Remission After TKI Discontinuation in Patients With CML - 2 year(s) ago
Approximately 20% of patients with chronic myeloid leukemia (CML) who discontinued tyrosine kinase inhibitor (TKI) therapy after maintaining deep molecular response for many years experienced disease recurrence requiring therapy, according to the results of a study that will be presented during the 2022 ASCO Annual Meeting (Abstract 7050).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Duration of deep molecular response associated w/ maintaining treatment-free remission after #TKI discontinuation in patients w/ #CML. https://t.co/rIbfogXVlW @FadiHaddad_MD #ASCO22 #ASCODailyNews #leusm
-
-
Mashup Score: 2Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pharmacy Forum: Asciminib is an oral #TKI that exhibits a novel mechanism of action which acts as a selective allosteric inhibitor of BCR-ABL1 kinase activity for #CML Philadelphia chromosome-positive (Ph+) disease: https://t.co/3wERmqhRox #cancerdrugs #pharmaonc https://t.co/GDkiUWcguc
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pharmacy Forum: Asciminib is an oral #TKI that exhibits a novel mechanism of action which acts as a selective allosteric inhibitor of BCR-ABL1 kinase activity for #CML Philadelphia chromosome-positive (Ph+) disease: https://t.co/3wERmqhRox #cancerdrugs #pharmaonc https://t.co/e5rhUxhnpY
-
-
Mashup Score: 0Hutson Reviews Multiple Combination Trials for Patients With RCC - 2 year(s) ago
During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmaD, discussed immunotherapy and tyrosine kinase inhibitor combinations for frontline therapy of renal cell carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmaD, discussed immunotherapy and tyrosine kinase inhibitor combinations for frontline therapy of renal cell carcinoma. #oncology #rcc #kcsm #tki https://t.co/B4zZ1C2yg8
-
-
Mashup Score: 0Demystifying Kidney Cancer - 2 year(s) ago
PatientsEngage and Biocon Biologics bring together an expert panel to talk about kidney cancer and answer questions and concerns that patients may have.The p…
Source: YouTubeCategories: Latest Headlines, Oncologists1Tweet-
#kidneycancer #kidneydiseaseawareness #genericmedicines #pazopanib #biocon #tki Link to the youtube feed https://t.co/o8jV5c6nv3 https://t.co/83XStiyInB
-
Patients with #CML, especially those over 60, who did not achieve a MMR, or even a CCyR, at two years after initiating #TKI therapy still had good long-term OS, according to a recent retrospective study https://t.co/q4YL1RFuVx